Incyte Corp. has created two new units in anticipation of future growth in the U.S. and internationally. A new U.S. country organization will lead commercial and medical affairs in the U.S., and a Global Product Strategy and Business Development & Licensing (BD&L) unit will lead global competitive strategies for Incyte’s portfolio beyond Jakafi (ruxolitinib).
 
Jim Daly will leave Incyte later this month, and commented, “My decision to return to California was a personal one. I leave Incyte knowing that the business is performing well and that the team is well-prepared to grow Jakafi, and to advance Incyte’s pipeline of innovative medicines, as the company seeks to make a major difference for cancer patients in the years ahead.”
 
Barry Flannelly, Pharm. D., has been appointed to the newly created position of executive vice president and general manager U.S. The existing U.S. commercial team will now report to Dr. Flannelly. A newly created position of head of Global Product Strategy and BD&L will be filled soon.
 
“Jim created significant commercial momentum for Incyte. We sincerely thank him for all his efforts, including driving towards our goals for Jakafi, and we wish him well,” said Hervé Hoppenot, Incyte’s president and chief executive officer. “Incyte has a large development portfolio and significant global opportunities, and now is the opportune time for us to organize the company to include both a regional operating unit for the U.S. as well as a global strategic product team. We are also delighted to be able to immediately move Barry into his new role and draw on his more than 20-year track record in the biopharma industry.”
 
Dr. Flannelly has been working in oncology since 1987, and began his career at Rhone-Poulenc Rorer, which later became Sanofi-Aventis. He has since held roles of increasing responsibility at Novartis, Abraxis Oncology, Onyx Pharmaceuticals and Nektar Therapeutics in medical affairs, strategic planning, and commercial operations.